US › Healthcare

Enanta Pharmaceuticals Inc (ENTA)

US · Healthcare · Biotechnology

$11.00+9.13%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$14.4M

Revenue YoY

-21.6%

Net profit

$-19.5M

EPS

$-0.67

EPS estimate

$-0.37

Net margin

-135.8%

EPS came in at -0.67 against a street estimate of -0.37 — a miss of 81.1%.

Key statistics

Market cap

$293.6M

Forward P/E

44.1

P/B

3.07

Book value

$3.47

EPS (TTM)

$-2.42

52-week high

$17.15

52-week low

$10.05

50-day MA

$12.33

200-day MA

$13.16

Beta

0.76

Analyst view

Analysts rate Enanta Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $21.83.

Shareholding

Insiders

4.67%

Institutions

94.47%

Largest institutional holders

Fund	Stake
HHG PLC	12.99%
Jupiter Topco LLC	12.55%
BlackRock Inc	11.14%
Krensavage Asset Management, LLC	9.84%
Farallon Capital Management, L.L.C.	8.30%
Deep Track Capital, LP	4.96%
ADAR1 Capital Management LLC	4.62%
Vanguard Capital Management, LLC	4.16%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enanta Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.